Skip to main content
https://pbs.twimg.com/media/GHxkQLzXoAAnOLG.jpg
Neonatal Fc receptor mAb (lowers Igs) development: 2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis 2023 FDA approved rozanolixizumab (Rystiggo) for MG 2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG INTERESTING? https://t.co/HB1fJet3Bo https://t.co/OBrd2Y3nye
Dr. John Cush
Mar-03-2024
×